相似文献
1
Estrogens, regulation of p53 and breast cancer risk: a balancing act.
Cell Mol Life Sci. 2010 Apr;67(7):1017-23. doi: 10.1007/s00018-009-0244-7.
2
miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells.
Breast Cancer Res. 2011;13(6):R116. doi: 10.1186/bcr3059. Epub 2011 Nov 23.
3
Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer.
Horm Cancer. 2017 Aug;8(4):230-242. doi: 10.1007/s12672-017-0298-1. Epub 2017 Jun 2.
4
Mouse mammary tumor-like virus is associated with p53 nuclear accumulation and progesterone receptor positivity but not estrogen positivity in human female breast cancer.
Clin Cancer Res. 2004 Jul 1;10(13):4417-9. doi: 10.1158/1078-0432.CCR-03-0232.
5
Biology of female sex hormone action in relation to contraceptive agents and neoplasia.
Contraception. 1991 Jun;43(6):527-42. doi: 10.1016/0010-7824(91)90002-w.
6
Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells.
PLoS One. 2018 Mar 28;13(3):e0194913. doi: 10.1371/journal.pone.0194913. eCollection 2018.
7
Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity.
Endocrinology. 2008 Oct;149(10):4809-20. doi: 10.1210/en.2008-0035. Epub 2008 Jun 12.
8
The p53-estrogen receptor loop in cancer.
Curr Mol Med. 2013 Sep;13(8):1229-40. doi: 10.2174/15665240113139990065.
9
Epigenetic regulation of estrogen signaling in breast cancer.
Epigenetics. 2013 Mar;8(3):237-45. doi: 10.4161/epi.23790. Epub 2013 Jan 30.
10
Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice.
Breast Cancer Res. 2008;10(3):R43. doi: 10.1186/bcr2094. Epub 2008 May 12.
引用本文的文献
1
Rosetta Stone for Cancer Cure: Comparison of the Anticancer Capacity of Endogenous Estrogens, Synthetic Estrogens and Antiestrogens.
Oncol Rev. 2023 Apr 19;17:10708. doi: 10.3389/or.2023.10708. eCollection 2023.
2
Adverse outcome pathways for ionizing radiation and breast cancer involve direct and indirect DNA damage, oxidative stress, inflammation, genomic instability, and interaction with hormonal regulation of the breast.
Arch Toxicol. 2020 May;94(5):1511-1549. doi: 10.1007/s00204-020-02752-z. Epub 2020 May 13.
3
Oxybenzone Alters Mammary Gland Morphology in Mice Exposed During Pregnancy and Lactation.
J Endocr Soc. 2018 May 22;2(8):903-921. doi: 10.1210/js.2018-00024. eCollection 2018 Aug 1.
4
Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence.
Cancers (Basel). 2018 May 31;10(6):172. doi: 10.3390/cancers10060172.
5
Long non-coding RNAs may serve as biomarkers in breast cancer combined with primary lung cancer.
Oncotarget. 2017 Apr 21;8(35):58210-58221. doi: 10.18632/oncotarget.17356. eCollection 2017 Aug 29.
6
Regulation of p53 level by UBE4B in breast cancer.
PLoS One. 2014 Feb 26;9(2):e90154. doi: 10.1371/journal.pone.0090154. eCollection 2014.
7
Interferon regulatory factor 4 binding protein is a novel p53 target gene and suppresses cisplatin-induced apoptosis of breast cancer cells.
Mol Cancer. 2012 Aug 13;11:54. doi: 10.1186/1476-4598-11-54.
8
Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.
Ann N Y Acad Sci. 2011 Jul;1229(1):147-55. doi: 10.1111/j.1749-6632.2011.06086.x.
9
RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α.
Oncogene. 2012 Jan 26;31(4):527-34. doi: 10.1038/onc.2011.252. Epub 2011 Jun 27.
10
Map making in the 21st century: charting breast cancer susceptibility pathways in rodent models.
J Mammary Gland Biol Neoplasia. 2011 Apr;16(1):57-64. doi: 10.1007/s10911-011-9201-9. Epub 2011 Mar 8.
本文引用的文献
1
The expanding universe of p53 targets.
Nat Rev Cancer. 2009 Oct;9(10):724-37. doi: 10.1038/nrc2730.
2
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
JAMA. 2009 Aug 19;302(7):774-80. doi: 10.1001/jama.2009.1204.
3
KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha.
Oncogene. 2009 Aug 13;28(32):2894-902. doi: 10.1038/onc.2009.151. Epub 2009 Jun 8.
4
Blinded by the Light: The Growing Complexity of p53.
Cell. 2009 May 1;137(3):413-31. doi: 10.1016/j.cell.2009.04.037.
5
Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells.
Cancer Res. 2009 Apr 15;69(8):3405-14. doi: 10.1158/0008-5472.CAN-08-3628. Epub 2009 Apr 7.
6
Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1.
Nat Genet. 2009 Mar;41(3):324-8. doi: 10.1038/ng.318. Epub 2009 Feb 15.
7
A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women.
Carcinogenesis. 2009 Jan;30(1):59-64. doi: 10.1093/carcin/bgn253. Epub 2008 Nov 20.
8
Genes and social behavior.
Science. 2008 Nov 7;322(5903):896-900. doi: 10.1126/science.1159277.
9
Strain-specific differences in the mechanisms of progesterone regulation of murine mammary gland development.
Endocrinology. 2009 Mar;150(3):1485-94. doi: 10.1210/en.2008-1459. Epub 2008 Nov 6.
10
Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells.
Toxicol Sci. 2008 Oct;105(2):303-11. doi: 10.1093/toxsci/kfn141. Epub 2008 Jul 21.
Zotero 插件